Document is current
Any future updates will be listed below
-
Authors
Murakawa, Masaaki
Kawahara, Shinnosuke
Takahashi, Daishi
Kamioka, Yuto
Yamamoto, Naoto
Kobayashi, Satoshi
Ueno, Makoto
Morimoto, Manabu
Sawazaki, Sho
Tamagawa, Hiroshi
Ohshima, Takashi
Yukawa, Norio
Rino, Yasushi
Morinaga, Soichiro
-
Funding
Funding for this research was provided by:
Bayer Yakuhin
Taiho Pharmaceutical
Takeda Pharmaceutical Company
Yakult Honsha
Eisai
Eli Lilly Japan
Chugai Pharmaceutical
Asahi Kasei Pharma Corporation
Abbott Japan
Zeria pharmaceutical
Daiichi-Sankyo
Tsumura and Company
Medtronic Japan
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 13 May 2023
Accepted: 8 August 2023
First Online: 24 August 2023
Declarations
:
: The Institutional Review Board Committee of the Kanagawa Cancer Center approved this study (2021eki-74, 21 Sep 2021). Informed consent was obtained from all individual participants included in the study.
: Yasushi Rino has received research grants from Taiho pharmaceutical, Abbott, Asahi Kasei, Zeria pharmaceutical, Daiichi-Sankyo, Tsumura & Co., Covidien, and Otsuka. Satoshi Kobayashi has received a speaker honorarium from Bayer Yakuhin, Taiho Pharmaceutical, Yakult Honsha, Eisai, Eli Lilly, Takeda Pharmaceutical, and Chugai Pharmaceutical. Masaaki Murakawa declares that he has no conflict of interest. Yuto Kamioka declares that he has no conflict of interest. Shinnosuke Kawahara declares that he has no conflict of interest. Naoto Yamamoto declares that he has no conflict of interest. Makoto Ueno declares that he has no conflict of interest. Manabu Morimoto declares that he has no conflict of interest. Hiroshi Tamagawa declares that he has no conflict of interest. Takashi Ohshima declares that he has no conflict of interest. Norio Yukawa declares that he has no conflict of interest. Soichiro Morinaga declares that he has no conflict of interest.
